Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Income Statement
Earnings Waterfall
Anebulo Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-10.7m
USD
|
Operating Income
|
-10.7m
USD
|
Other Expenses
|
156k
USD
|
Net Income
|
-10.5m
USD
|
Income Statement
Anebulo Pharmaceuticals Inc
Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||
Operating Expenses |
(6)
|
(7)
|
(7)
|
(8)
|
(11)
|
(12)
|
(12)
|
(12)
|
(11)
|
|
Selling, General & Administrative |
(3)
|
(3)
|
(4)
|
(4)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
|
Research & Development |
(3)
|
(4)
|
(3)
|
(3)
|
(5)
|
(5)
|
(6)
|
(6)
|
(5)
|
|
Operating Income |
(6)
N/A
|
(7)
-24%
|
(7)
+2%
|
(8)
-16%
|
(11)
-35%
|
(12)
-9%
|
(12)
-1%
|
(12)
+1%
|
(11)
+9%
|
|
Pre-Tax Income | ||||||||||
Interest Income Expense |
(27)
|
(27)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
|
Pre-Tax Income |
(32)
N/A
|
(34)
-4%
|
(7)
+80%
|
(8)
-15%
|
(11)
-35%
|
(12)
-9%
|
(12)
-1%
|
(12)
+1%
|
(10)
+10%
|
|
Net Income | ||||||||||
Income from Continuing Operations |
(32)
|
(34)
|
(7)
|
(8)
|
(11)
|
(12)
|
(12)
|
(12)
|
(10)
|
|
Net Income (Common) |
(40)
N/A
|
(34)
+17%
|
(7)
+80%
|
(8)
-15%
|
(11)
-35%
|
(12)
-9%
|
(12)
-1%
|
(12)
+1%
|
(10)
+10%
|
|
EPS (Diluted) |
-1.73
N/A
|
-1.43
+17%
|
-0.29
+80%
|
-0.34
-17%
|
-0.41
-21%
|
-0.47
-15%
|
-0.47
N/A
|
-0.46
+2%
|
-0.41
+11%
|